세계의 바이오마커 시장 규모는 2023년 637억 달러, 2024년 705억 달러에서 예측 기간 동안 CAGR 13.1%로 추이하고 2029년 말에는 1,302억 달러에 달할 것으로 예측됩니다.
소모품 부문은 2024년 408억 달러에서 예측 기간 동안 CAGR 12.7%로 추이하고, 2029년 말에는 740억 달러에 이를 것으로 예측됩니다. 장비 부문은 2024년 175억 달러에 이르고, CAGR 14.1%로 추이하고 2029년 말에는 339억 달러에 이를 것으로 예측됩니다.
본 보고서에서는 세계 바이오마커의 기술과 시장을 조사했으며, 시장 개요, 시장영향인자 및 시장 기회 분석, 법규제 환경, 신흥기술 및 기술 개발 동향, 시장 규모 추이와 예측, 각종 구분· 지역별 상세 분석, 경쟁 구도, 주요 기업 프로파일 등을 정리했습니다.
목차
제1장 주요 요약
제2장 시장 개요
- 개요
- 바이오마커의 분류
- 바이오마커의 예
- 감수성/리스크 바이오마커
- 진단 바이오마커
- 모니터링 바이오마커
- 예후 바이오마커
- 예측 바이오마커
- 약역학(반응) 바이오 마커
- 안전성 바이오마커
- 대체 바이오마커/엔드포인트
- 발견, 검증, 검증
- 바이오마커의 적격성
- 바이오마커의 응용
- 진단, 치료, 질환 모니터링
- 의약품의 발견과 개발
- 임상시험
제3장 시장 역학
- 개요
- 시장 성장 촉진요인
- 병의 발생률의 상승
- 오믹스와 이미징 기술의 진보
- 시장 성장 억제요인
- 높은 개발 비용
- 기술을 가진 인재의 요건
- 시장 기회
- 신흥 시장
- 맞춤형 의료
제4장 신기술과 개발
- 개요
- 신흥기술
- 유전체학
- 단백질체학
- 대사체학
- 이미징
- 바이오인포매틱스
- 임상시험
- 임상시험 분석 : 치료영역별
- 임상시험 분석 : 연구 상황별
- 임상시험 분석 : 연구 유형별
- 특허 분석
제5장 시장 세분화 분석
- 시장 동향
- 세분화의 내역
- 바이오 마커 : 세계 시장
- 시장 분석 : 제품 유형별
- 소모품
- 기기
- 서비스
- 소프트웨어
- 시장 분석 : 기술별
- 단백질체학
- 유전체학
- 이미징
- 바이오인포매틱스
- 대사체학
- 시장 분석 : 치료 영역별
- 암
- 심장혈관 및 대사질환
- 신경퇴행성 질환
- 감염증
- 자가면역질환
- 기타
- 시장 분석 : 최종 사용자별
- 병원 및 진단실험실
- 학술연구기관
- 제약·바이오테크놀러지 기업
- CRO
- 지리적 내역
- 시장 분석 : 지역별
- 북미
- 유럽
- 아시아태평양
- 기타 지역
제6장 경쟁 정보
제7장 바이오마커의 각종 기술과 세계 시장에서의 지속가능성 : ESG의 관점
- 바이오마커 시장에서의 지속가능성
- ESG 위험과 등급: 데이터 이해
- BCC에 의한 견해
제8장 부록
- 조사 방법
- 출처
- 약어
- 기업 프로파일
- ABBOTT
- AGILENT TECHNOLOGIES INC.
- BAYER AG
- BD
- BIO-RAD LABORATORIES INC.
- BRUKER
- DANAHER CORP.
- F. HOFFMANN-LA ROCHE LTD.
- FUJIFILM HOLDINGS CORP.
- GE HEALTHCARE
- ILLUMINA INC.
- JEOL LTD.
- KONINKLIJKE PHILIPS NV
- PROMEGA CORP.
- QIAGEN
- REVVITY
- SHIMADZU CORP.
- SIEMENS HEALTHINEERS AG
- THERMO FISHER SCIENTIFIC INC.
JHS
The global market for biomarkers was valued at $63.7 billion in 2023. This market is expected to grow from $70.5 billion in 2024 to $130.2 billion by the end of 2029, at a compound annual growth rate (CAGR) of 13.1% from 2024 through 2029.
The global market for biomarker consumables is expected to grow from $40.8 billion in 2024 to $74.0 billion by the end of 2029, at a CAGR of 12.7% from 2024 through 2029.
The global market for biomarker instruments is expected to grow from $17.5 billion in 2024 to $33.9 billion by the end of 2029, at a CAGR of 14.1% from 2024 through 2029.
Report Scope:
The scope of this report on the global market for biomarker technologies encompasses an analysis of the current landscape, including market size, growth trends and segmentation by product type, technology, therapeutic area and end user. The report breaks down the market into several product categories: instruments, consumables (such as reagents, kits and panels), services and software. It also segments the market by technology: genomics, proteomics, metabolomics, imaging and bioinformatics. It also examines the biomarker market across the therapeutic areas of cancer; cardiovascular, metabolic, infectious and neurodegenerative diseases; and autoimmune disorders. The end-user segments are academic institutions, pharmaceutical and biotechnology companies, clinical research organizations, hospitals and diagnostic centers.
By region, the analysis encompasses North America, Europe, Asia-Pacific, and the Rest of the World (RoW). The report also includes profiles of leading companies and highlights industry trends, major products, mergers and acquisitions, and other collaborations or partnerships.
Report Includes:
- 34 data tables and 62 additional tables
- An up-to-date overview of the global markets and technologies for biomarkers
- Analysis of the global market trends, with data from 2021-2023, estimates for 2024, and projections of compound annual growth rates (CAGRs) through 2029
- Evaluation of the size and revenue growth prospects, accompanied by a market share analysis by product type, technology, therapeutic area, end user, and region
- Assessment of market dynamics such as drivers, restraints and opportunities
- Coverage of major types of biomarkers and their use in clinical trial assessment, drug discovery and development, and therapeutics
- Review of patents issued for biomarker technologies and deep dive of patent data by year, technology type, application, company, assignee and applicant country
- A discussion on ESG challenges and practices in the industry
- Assessment of the vendor landscape, including the market shares of key companies, their product portfolios and financial overviews
- Information on recent mergers, acquisitions, expansions, collaborations, investments, divestments, product launches, and other strategic developments
- Profiles of the leading companies, including F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Illumina Inc., Bio-Rad Laboratories Inc., and Agilent Technologies Inc.
Table of Contents
Chapter 1 Executive Summary
- Market Outlook
- Scope of Report
- Market Summary
Chapter 2 Market Overview
- Overview
- Classification of Biomarkers
- Examples of Biomarkers
- Susceptibility/Risk Biomarkers
- Diagnostic Biomarkers
- Monitoring Biomarkers
- Prognostic Biomarkers
- Predictive Biomarkers
- Pharmacodynamic (Response) Biomarkers
- Safety Biomarkers
- Surrogate Biomarkers/Endpoints
- Discovery, Verification and Validation
- Biomarker Qualification
- Applications of Biomarkers
- Diagnostics, Therapeutics and Disease Monitoring
- Drug Discovery and Development
- Clinical Trials
Chapter 3 Market Dynamics
- Overview
- Market Drivers
- Rising Incidence of Diseases
- Advances in Omics and Imaging Technologies
- Market Restraints
- High Development Costs
- Requirement for Skilled Labor
- Market Opportunities
- Emerging Markets
- Personalized Medicine
Chapter 4 Emerging Technologies and Developments
- Overview
- Emerging Technologies
- Genomics
- Proteomics
- Metabolomics
- Imaging
- Bioinformatics
- Clinical Trials
- Clinical Trial Analysis, by Therapeutic Area
- Clinical Trial Analysis, by Study Status
- Clinical Trial Analysis, by Study Type
- Patent Analysis
Chapter 5 Market Segmentation Analysis
- Market Trends
- Segmentation Breakdown
- Biomarkers: Global Markets
- Market Analysis by Product Type
- Consumables
- Instruments
- Services
- Software
- Market Analysis by Technology
- Proteomics
- Genomics
- Imaging
- Bioinformatics
- Metabolomics
- Market Analysis by Therapeutic Area
- Cancer
- Cardiovascular and Metabolic Diseases
- Neurodegenerative Diseases
- Infectious Diseases
- Autoimmune Diseases
- Other Diseases
- Market Analysis by End User
- Hospitals and Diagnostic Labs
- Academic and Research Institutes
- Pharmaceutical and Biotech Companies
- Contract Research Organizations
- Geographic Breakdown
- Market Analysis by Region
- North America
- Europe
- Asia-Pacific
- Rest of the World
Chapter 6 Competitive Intelligence
- Ranking of Companies in the Biomarker Industry
Chapter 7 Sustainability in Biomarkers Technologies and Global Markets: An ESG Perspective
- Sustainability in the Biomarker Market
- ESG Risks and Ratings: Understanding the Data
- BCC Research Viewpoint
Chapter 8 Appendix
- Methodology
- Sources
- Abbreviations
- Company Profiles
- ABBOTT
- AGILENT TECHNOLOGIES INC.
- BAYER AG
- BD
- BIO-RAD LABORATORIES INC.
- BRUKER
- DANAHER CORP.
- F. HOFFMANN-LA ROCHE LTD.
- FUJIFILM HOLDINGS CORP.
- GE HEALTHCARE
- ILLUMINA INC.
- JEOL LTD.
- KONINKLIJKE PHILIPS N.V.
- PROMEGA CORP.
- QIAGEN
- REVVITY
- SHIMADZU CORP.
- SIEMENS HEALTHINEERS AG
- THERMO FISHER SCIENTIFIC INC.
